Loading...
Market
Will Susvimo eye implant sales exceed $100 million in the US by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Genentech quarterly financial reports
Story
Genentech, Roche Unit, Reintroduces Susvimo Eye Implant After Recall
Jul 8, 2024, 07:24 PM
Genentech, a unit of Roche Group, has announced the reintroduction of its eye implant, Susvimo, in the United States. The implant is designed for people with wet age-related macular degeneration (AMD), a blinding eye disease. The re-launch follows the end of a voluntary recall that took place two years ago. Susvimo, which was recalled, is a refillable implant, and it will be available to patients in the coming weeks. The announcement was made on Monday.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
